Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110183338 | TWO STAGE ENRICHMENT OF CELL-FREE FETAL DNA IN MATERNAL PLASMA The present invention provides methods for enriching fetal nucleic acid in a biological sample from a maternal host. Also provided are methods for detecting the presence or absence of markers in fetal, tumor, or neoplastic nucleic acid. The methods can include treating ... | 07/28/2011 |
| 20110171640 | Method for isolating cell free apoptotic or fetal nucleic acids The present invention provides methods for isolating cell free nucleic acid, e.g., apoptotic or fetal nucleic acids and methods of detecting neoplastic cells or identifying the genetic composition of a fetus. The invention also provides magnetic particles comprising an ... | 07/14/2011 |
| 20110158977 | Immunogenic compositions for Chlamydia trachomatis The present invention provides variant LcrE sequences and/or combinations of variant LcrE sequences across the Chlamydia trachomatis serovars. Such changes in LcrE genotypes across the Chlamydia trachomatis serovars are likely to correspond with changes in... | 06/30/2011 |
| 20110110982 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence... | 05/12/2011 |
| 20110065146 | Expression of HIV polypeptides and production of virus-like particles The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are... | 03/17/2011 |
| 20110052632 | HIV POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM BOTSWANA MJ4 The present disclosure relates to novel polynucleotides that encode HIV Env polypeptides. In particular, the disclosure relates to sequences derived from HIV strain Botswana MJ4 encoding Env polypeptides. Compositions comprising these polynucleotides and methods of usin... | 03/03/2011 |
| 20110045017 | HIV VACCINE FOR MUCOSAL DELIVERY This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be us... | 02/24/2011 |
| 20110033456 | METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or anti... | 02/10/2011 |
| 20110020396 | HIV Envelope-CD4 Complexes and Hybrids Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.... | 01/27/2011 |
| 20110020352 | ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.... | 01/27/2011 |
| 20110002958 | Alphavirus Vectors for Respiratory Pathogen Vaccines Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, and alphavirus replicon p... | 01/06/2011 |
| 20100330121 | RECOMBINANT ALPHAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACRO-MOLECULAR SYNTHESIS Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vecto... | 12/30/2010 |
| 20100316698 | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.... | 12/16/2010 |
| 20100266631 | Compositions and Methods for Generating an Immune Response Utilizing Alphavirus-Based Vector Systems Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.... | 10/21/2010 |
| 20100196368 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment ... | 08/05/2010 |
| 20100196339 | Microparticle-Based Transfection and Activation of Dendritic Cells The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleoti... | 08/05/2010 |
| 20100172912 | METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or anti... | 07/08/2010 |
| 20100092502 | MODIFIED HIV ENV POLYPEPTIDES Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.... | 04/15/2010 |
| 20100040676 | POLYCISTRONIC HIV VECTOR CONSTRUCTS The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comp... | 02/18/2010 |
| 20100021548 | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE RESPONSES The use of poly(lactide) or poly(lactide-co-glycolide) microparticles with adsorbed antigen is disclosed. The microparticles are useful for enhancing CTL responses to a selected antigen.... | 01/28/2010 |
| 20090305344 | CHIMERIC ALPHAVIRUS REPLICON PARTICLES Chimeric alphaviruses and alphavirus replicon particles are provided, including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or e... | 12/10/2009 |
| 20090252738 | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix Compositions and methods useful in inhibiting proliferation of CA IX+preneoplastic or neoplastic cells in a mammal are provided. The compositions are antagonist anti-CA IX antibodies and other inhibitory agents that target carbonic anhydrase activity of CA IX on these c... | 10/08/2009 |
| 20090221504 | DOSE OF AN ANGIOGENIC FACTOR AND METHOD OF ADMINISTERING TO IMPROVE MYOCARDIAL BLOOD FLOW The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angio... | 09/03/2009 |
| 20090170776 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present inve... | 07/02/2009 |
| 20090131304 | Semi-Synthetic Desmethyl-Vancomycin-Based Glycopeptides With Antibiotic Activity Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conve... | 05/21/2009 |
| 20090087447 | Novel HCV non-structural polypeptide Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these pol... | 04/02/2009 |
| 20090081254 | HIV VACCINE FOR MUCOSAL DELIVERY This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be us... | 03/26/2009 |
| 20090081242 | METHODS OF THERAPY FOR B-CELL MALIGNANCIES USING ANTAGONIST ANTI-CD40 ANTIBODIES Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or anti... | 03/26/2009 |
